GlassScriptPhysician profile
James Mark Anderson
NPI 1225004351
$11,503.63
in general payments reported to CMS, 2019-2025
38 companies · $313 in 2025
The $313 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $301 · 2020: $103 · 2021: $627 · 2022: $1,536 · 2023: $77.25 · 2024: $8,547 · 2025: $313.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $6,018 · Travel and Lodging: $1,987 · Food and Beverage: $933.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $6,017.50 |
| Travel and Lodging | $1,987.19 |
| Food and Beverage | $932.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironshore Pharmaceuticals INC. | $8,505.34 | 2024 | |
| Abbvie INC. | $420.09 | 2019-2022 | |
| Abbott Laboratories | $355.03 | 2021-2025 | Confirm Rx |
| Glaxosmithkline, LLC. | $253.62 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $218.13 | 2022 | |
| Novo Nordisk INC | $185.69 | 2021-2022 | |
| Lilly USA, LLC | $167.01 | 2021-2022 | |
| Stryker Corporation | $137.65 | 2025 | Artix Mt |
| Amgen INC. | $117.75 | 2021-2022 | |
| Amarin Pharma, INC. | $89.76 | 2019-2022 | |
| Allergan, INC. | $87.24 | 2019-2020 | |
| Cleerly, INC. | $85.47 | 2023-2025 | Cleerly Labs, Cleerly Ischemia |
| Biohaven Pharmaceutical Holding Company LTD. | $80.76 | 2022 | |
| Pfizer INC. | $66.97 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $63.86 | 2019-2021 |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $60.20 | 2022 | |
| Merck Sharp & Dohme LLC | $59.89 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $55.10 | 2019 | |
| Supernus Pharmaceuticals, INC. | $52.77 | 2022-2023 | Qelbree |
| Vertical Pharmaceuticals, LLC | $45.72 | 2025 | Relexxii |
| Dexcom, INC. | $38.05 | 2022-2023 | Dexcom G6 Transmitter |
| Mannkind Corporation | $36.55 | 2020 | |
| Jazz Pharmaceuticals INC. | $30.97 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $28.06 | 2021-2022 | |
| Eisai INC. | $24.99 | 2022 | |
| Astellas Pharma US INC | $23.05 | 2019-2022 | |
| Tris Pharma INC | $22.55 | 2022 | |
| Abiomed | $22.39 | 2019 | |
| Viiv Healthcare Company | $22.39 | 2022 | |
| Upsher-Smith Laboratories LLC | $20.35 | 2022 | |
| Arbor Pharmaceuticals, INC. | $19.06 | 2021 | |
| Sanofi Pasteur INC. | $18.23 | 2022 | |
| Acrotech Biopharma INC. | $18.22 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.22 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $14.68 | 2022 | |
| Althera Pharmaceuticals LLC | $14.11 | 2021 | |
| Ge Healthcare | $12.93 | 2020 | |
| Antares Pharma, INC. | $12.78 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Anderson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.